Kiromic BioPharma, Inc.
7707 Fannin Street, Suite 140
Houston, TX 77054
ADDITIONAL DEFINITIVE PROXY MATERIAL
On July 17, 2023, Kiromic BioPharma, Inc. (the “Company”) announced that its Board of Directors has approved an amendment and restatement of the Company’s Bylaws to reduce the quorum needed for stockholder meetings to one-third (33.33%) of the shares issued and outstanding and entitled to vote at a meeting of stockholders. The quorum requirement was also applied retroactively to the 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting will be held on Tuesday July 25, 2023, beginning at 9:00 a.m. Central Time at the Company’s offices, located at 7707 Fannin Street, Suite 140, Houston, TX 77054.
To date, the holders of approximately 26% of our outstanding shares have cast proxies to vote at the Annual Meeting, and such votes are supportive of the proposals submitted to stockholders. If you have voted by proxy already, your vote will be counted – there is no need to take any further action. If for any reason you wish to revoke your proxy, please follow the instructions in the Proxy Statement for the Annual Meeting.
This document amends and supplements the Proxy Statement for the Annual Meeting, dated and originally sent to stockholders on June 20, 2023, to reflect the new quorum requirement applicable to the Annual Meeting.
The following Question and Answer is added to the Proxy Statement:
What constitutes a quorum at the Annual Meeting?
The presence, by registering and participating in the Annual Meeting or by submitting a proxy, of the holders of one-third (33.33%) of the outstanding shares of Common Stock is necessary to constitute a quorum at the meeting. Abstentions in each of the proposals will be counted for the purpose of determining whether a quorum is present at the meeting and as votes cast and will have the effect of a negative vote. Broker non-votes will be counted for the purpose of determining the existence of a quorum at the Annual Meeting.
The record date for the Annual Meeting remains as June 9, 2023.